Australian biotech giant CSL Ltd (CSL) logged a jump in its first-half profit on Tuesday due to strong demand in all key segments, while increased plasma collection at its Behring unit bolstered revenue contributions.
The company, which uses blood plasma to create treatments for certain diseases, posted a statutory net profit after tax, excluding one-off items, of $2.06 billion on a constant currency basis for the half year ended Dec. 31, up 13% from a year ago.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$265.50 |
Change
1.550(0.59%) |
Mkt cap ! $128.5B | |||
| Open | High | Low | Value | Volume |
| $264.45 | $265.88 | $259.33 | $230.1M | 870.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27 | $265.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $265.80 | 79 | 1 |
View Market Depth
| Last trade - 16.12pm 23/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |